Galectin Therapeutics Inc [GALT] stock is trading at $6.3, up 10.53%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The GALT shares have gain 9.38% over the last week, with a monthly amount glided 11.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright reaffirmed its Buy rating on August 13, 2020, and elevated its price target to $12. On February 13, 2019, B. Riley FBR initiated with a Buy rating and assigned a price target of $11 on the stock. H.C. Wainwright reiterated its Buy rating and increased its price target to $10 on December 07, 2017. H.C. Wainwright reiterated its recommendation of a Buy and raised its price target to $6 on November 28, 2017. In a note dated March 30, 2017, H.C. Wainwright upgraded a Buy rating on this stock but restated the target price of $3.50.
Galectin Therapeutics Inc [GALT] stock has fluctuated between $0.73 and $6.55 over the past year. Galectin Therapeutics Inc [NASDAQ: GALT] shares were valued at $6.3 at the most recent close of the market.
Analyzing the GALT fundamentals
Gross Profit Margin for this corporation currently stands at 0.17% with Operating Profit Margin at -693.06%, Pretax Profit Margin comes in at -1036.19%, and Net Profit Margin reading is -1036.19%. To continue investigating profitability, this company’s Return on Assets is posted at -2.9, Equity is 0.33 and Total Capital is 0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.99.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.84 points at the first support level, and at 5.38 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.64, and for the 2nd resistance point, it is at 6.98.
Ratios To Look Out For
For context, Galectin Therapeutics Inc’s Current Ratio is 0.09. Also, the Quick Ratio is 0.09, while the Cash Ratio stands at 0.08.
Transactions by insiders
Recent insider trading involved 10X Fund, L.P., 10% Owner, that happened on Dec 03 ’25 when 0.12 million shares were sold. 10% Owner, 10X Fund, L.P. completed a deal on Dec 02 ’25 to sell 30000.0 shares. Meanwhile, President and CEO LEWIS JOEL sold 15680.0 shares on Nov 17 ’25.
